Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder.
Bipolar disorder (BD) has been associated with a proinflammatory state in which TNF-α seems to play a relevant role. The aim of the present study was to evaluate the plasma levels of TNF-α and its soluble receptors (sTNFR1 and sTNFR2) in BD patients in mania and euthymia in comparison with control subjects. We evaluated 53 BD patients (34 in mania and 19 in euthymia) and 38 healthy subjects. All subjects were assessed by the Mini-International Neuropsychiatry Interview (MINI-Plus). Patients were also evaluated by the Young Mania Rating Scale (YMRS) and by Hamilton Depression Rating Scale (HDRS). Plasma TNF-α and its soluble receptors were measured by ELISA. The plasma TNF-α and sTNFR2 levels did not differ between groups, but higher sTNFR1 levels were found in BD patients. Of note, BD patients in mania had higher sTNFR1 levels than BD patients in euthymia and controls. The sTNFR1 and sTNFR2 levels correlated with BD duration, and sTNFR2 levels correlated with age of patients. Our data indicate a proinflammatory status in BD patients during mania and further suggest that inflammatory mechanisms may be involved with the physiopathology of BD.
Barbosa
Izabela Guimarães
IG
Neuroscience Program, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.
Huguet
Rodrigo Barreto
RB
Mendonça
Vanessa Amaral
VA
Sousa
Lirlândia Pires
LP
Neves
Fernando Silva
FS
Bauer
Moisés Evandro
ME
Teixeira
Antônio Lúcio
AL
D000328:Adult; D000367:Age Factors; D000368:Aged; D001714:Bipolar Disorder / Q000097:blood* / Q000145:classification; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood*; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha
J Neuroimmunol. 2009 Nov 30;216(1-2):122-5
19732964
Acta Neurobiol Exp (Wars). 2008;68(4):526-34
19112477
Clin Endocrinol (Oxf). 2007 Nov;67(5):784-9
17697007
J Affect Disord. 2007 Dec;104(1-3):91-5
17434599
J Clin Psychiatry. 2009 Aug;70(8):1078-90
19497250
Bipolar Disord. 2007 Sep;9(6):596-602
17845274
JAMA. 2005 May 25;293(20):2528-30
15914754
Br J Soc Clin Psychol. 1967 Dec;6(4):278-96
6080235
Psychiatry Clin Neurosci. 2009 Apr;63(2):202-8
19175760
J Affect Disord. 2009 Aug;116(3):214-7
19251324
Psychopharmacology (Berl). 2005 May;179(2):447-51
15565432
Int J Obes Relat Metab Disord. 1998 Dec;22(12):1239-43
9877261
Eur Psychiatry. 2008 Sep;23(6):421-9
18504118
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
9881538
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1355-61
18316149
Neuroimmunomodulation. 2008;15(2):140-4
18679053
J Affect Disord. 2010 Jan;120(1-3):245-8
19446343
J Clin Psychiatry. 2008;69 Suppl 3:31-7
18533760
J Affect Disord. 2006 Feb;90(2-3):263-7
16410025
Br J Psychiatry. 1978 Nov;133:429-35
728692
Int J Neuropsychopharmacol. 2009 May;12(4):447-58
18771602
Cytokine Growth Factor Rev. 1996 Oct;7(3):231-40
8971478
Eur Arch Psychiatry Clin Neurosci. 2008 Jun;258 Suppl 2:97-106
18516521
Am J Psychiatry. 2000 May;157(5):683-94
10784457
J Psychiatr Res. 1999 Sep-Oct;33(5):407-18
10504009
Eur Arch Psychiatry Clin Neurosci. 2008 Aug;258(5):300-4
18297417